Cefuroxime Axetil
Brand names: Cefuroxime
At a glance
- Medicare prescriptions, 2024
- 773,029
- Medicare drug cost
- $11.5M
- Average cost per prescription
- $14.88
- Clinicians who prescribed it
- 25,835
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Cefuroxime axetil tablets are a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: Pharyngitis/tonsillitis (adults and pediatric patients) Acute bacterial otitis media (pediatric patients) Acute bacterial maxillary sinusitis (adults and pediatric patients) Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older) Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older) Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older) Uncomplicated gonorrhea (adults and pediatric patients 13 years and older) Early Lyme disease (adults and pediatric patients 13 years and older) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Pharyngitis/
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 25.5%
- Family Medicine 19.3%
- Nurse Practitioners 14.1%
- Physician Assistants 10.0%
- Urology 7.9%
- Emergency Medicine 7.4%
- Hospitalist 3.2%
- ENT (Otolaryngology) 2.4%
- Pulmonology 2.3%
- Infectious Disease 1.6%
- Geriatric Medicine 0.9%
- General Practice 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 5% from 2019 to 2024.
Biggest change by state since 2019
- Michigan +43%
- Minnesota +16%
- Colorado +11%
- Oregon +11%
- Washington +10%
- Puerto Rico (smallest change) −33%
- Kansas (smallest change) −27%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white oval tablet, 20 mm | A34 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | blue capsule, 19 mm | 203 |
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | white oval tablet, 16 mm | A33 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white oval tablet, 20 mm | A34 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.